

BIOGRAPHICAL SKETCH

POSITION TITLE

Dr Jaime Bosch**Professor of Medicine**

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
I.N.E.M. Girona	Bachiller (BS)	1964	Science
University of Barcelona Medical School	M.D.	1970	Medicine
University of Barcelona	Ph. D	1973	Liver-HRS
Hospital Clínic, University of Barcelona	Board Certified	1974 1979	Internal Medicine Gastroenterolgy
Yale University, School of Medicine and Liver Unit	Postdoctoral	1980-82	Hepatic Hemodynamics

A. Positions and Honors.**Positions**

1. Faculty member, Liver Unit, Hospital Clínic, University of Barcelona (1979-1985)
2. Chief of Section, Liver Unit and Hepatic Hemodynamic Lab, Hospital Clínic, Barcelona (1985-2012)
3. Associate Professor of Medicine, University of Barcelona, 1980-1985
4. Professor of Medicine, University of Barcelona, School of Medicine (1985-)
5. Sabbatical: Visiting Professor of Medicine, Yale University (August 1999-January 2000)
6. Chief of the Liver Unit, Hospital Clínic, University of Barcelona (1999-2003)
7. Senior Consultant Hepatologist, Hospital Clínic (2002-)
8. Chair of Medicine, University of Barcelona, (2003-)
9. Scientific Director, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Ministry of Science and Innovation. (10/2006-10/2015)
10. Guest Professor of Medicine, Bern University (2015-)

Other Experience and Professional Memberships

1. Member of the Scientific Committee, European Association for the Study of the Liver (1980-1983)
2. Member of the Selection Committee, Sociedad Española para el Estudio del Hígado (1985-1990)
3. Advisor to the Catalan Agency for Medical Technology Assessment and Science (1990-2005)
4. General Manager, National Health Research Program, Interministerial Commission for Science (1995-98).
5. Advisor to the Ministry of Education and Culture, Madrid (1998-1999)
6. President, Catalan Society of Gastroenterology (1996-1998)
7. Member of the Ethics Committee, Hospital Clínic (1997-2010)
8. Research Coordinator, Digestive Diseases Institute, Hospital Clínic (1998-2010)
9. Member of the Advisory Committee to the Director, IDIBAPS (2000-)
10. Associate Editor, Hepatology (1996-2001)
11. Associate Editor and Guest Editor, Seminars in Liver Diseases (1999-2004)
12. Associate Editor, Journal of Hepatology (2004-09)
13. Scientific Coordinator, National Research Network of Hepatology and Gastroenterology (2003-6).
14. President, Research Commission; School of Medicine, University of Barcelona (2004-2009).
15. Member of the Commission for Cooperative Medical Research, Instituto de Salud Carlos III, Madrid (2005-7)

16. Member of the Council for Scientific Policy, Ministry of Health, Madrid (2005-9).
17. President, Asociación Española para Estudio del Hígado (AEEH) (2013-2015).

Honors

1. Award to the best graduate of the Medical School, University of Barcelona (1970) Caixa de Pensions.
2. Awards for the Best Oral Presentation and Best Poster Presentation to the Meetings of the Spanish Association for the Study of the Liver (1975, 1977, 1980, 1985, 1992, 1996,2000,2007), Catalan Society of Gastroenterology (1982, 1984, 197, 1990) and European Association for the Study of the Liver (1985, 1989, 1993, 1999,2007).
3. Award of the Catalan College of Physicians to Professional Excellence, Medical Research (2005)
4. Special Recognition Award, European Association for the Study of the Liver (2006) (*JHepatol*,2006; 45:464-465).
5. Gold Medal, Canadian Association for the Study of the Liver (CASL). Montreal, February 2012.
6. Fellow, Royal College of Physicians, London, June 2012-.
7. Lilly Foundation Award, May 2013.
9. Doctor **Honoris Causa** in Medical Sciences, School of Medicine, University of Toulouse, France (2014).

B. List of publications in International journals (since 2009)

1. **Bosch J**. Towards the non-invasive diagnosis of cirrhosis: The nuts-cirrhosis connection. *J Hepatol*. 2009 Jan;50(1):4-6. PMID: 19019481 (Editorial)
 2. Angermayr B, Luca A, König F, Bertolini G, Ploner M, Gridelli B, Ulbrich G, Reiberger T, **Bosch J**, Peck-Radosavljevic M. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. *Eur J Clin Invest*. 2009 Jan;39(1):65-71.
 3. Laviña B, Gracia-Sancho J, Rodríguez-Vilarrupla A, Chu Y, Heistad DD, **Bosch J**, García-Pagán JC. Superoxide dismutase gene transfer reduces portal pressure in ccl4 cirrhotic rats with portal hypertension. *Gut*. 2009 Jan;58(1):118-25.
 4. Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, **Bosch J**, Fernandez M. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. *J Hepatol*. 2009 (50); 296-305.
 5. Dominguez M, Miquel R, Colmenero J, Moreno M, García-Pagán JC, **Bosch J**, Arroyo V, Ginès P, Caballería J, Bataller R. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. *Gastroenterology*. 2009;136:1639-1650.
 6. Abrales J, Albillos A, Bañares R, Turnes J, González R, García-Pagán J, **Bosch J**. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology*. 2009;136: 1651-1658.
 7. Mejias M, Garcia-Pras E, Tiani C, Miquel R, **Bosch J**, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. *Hepatology*. 2009 Apr;49(4):1245-56.
 8. Garcia-Pagan JC, Villanueva C, Albillos A, Bañares R, Morillas R, Abrales JG, **Bosch J**. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: A multicenter randomized controlled trial. *Gut*. 2009 Aug;58(8):1144-50.
 9. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, **Bosch J**, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan J, Patch D, Matloff DS, Makuch R, Rendon G; Portal Hypertension Collaborative Group. Incidence, prevalence and clinical significance of abnormal hematological indices in compensated cirrhosis. *Clin Gastroenterol Hepatol*. 2009 Jun;7(6):689-95.
 10. Ripoll C, Groszmann RJ, Garcia-Tsao G, **Bosch J**, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; the Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. *J Hepatol*. 2009 May;50(5):923-8
-

11. Chang PE, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG, **Bosch J**, Garcia-Pagan JC. Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy. Am J Gastroenterol. 2009 Jul;104(7):1707-14.
 12. La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia A-Pagán JC, **Bosch J**. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol. 2009 Aug;51(2):279-87.
 13. Murad SD, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL; EN-Vie (European Network for Vascular Disorders of the Liver). Collaborators (99): Bourgeois N, Dewaide J, Gruselle P, Martinet JP, O'Grady J, Burroughs A, Patch D, McGilchrist A, Thomas G, Swift J, Higginson T, Davies MH, Kapaida S, Catnach S, Leebeek FW, Tielemans WC, Rijken DC, van Buuren HR, Metselaar HJ, de Man RA, Malfliet JJ, Keizerwaard A, van Santen LA, Hansen B, Apericio-Pages MN, van Erpecum KJ, van der Linde K, Tjwa ET, Lieveerse RJ, Bac DJ, Achahboun M, Marot A, Durand F, Durand V, Cazals-Hatem D, Videau D, Deninger MH, Belghitti J, Condat B, Bureau C, Chagneau-Derrode C, Gorla O, Hillaire S, Nousbaum JB, Dao MT, D'Alterroche L, Lebray P, Sondag, De Kerguenec C, Rosenbaum A, Bartoli E, Habersetszer F, Mathurin P, Scoazec JY, Marteau P, Buffet C, Rossle M, Minoli G, Spinzi G, Boschetti C, Dell'Era A, Nicolini A, Marra F, Vizzutti F, De Santis A, Berzigotti A, Zoli M, Bellis L, Puoti C, Lozano R, Geva F, Abraldes JG, **Bosch J**, Cervantes F, Reverter JC, Ayuso JR, Gilabert R, Garcia-Criado A, Fuster J, Saez R, Baringo A, Rocabert L, Suarez Sambade D, Fernández-Bermejo M, Berenguer M, Aguilera V, de la Mata M, Bustamante J, Bañares Bañares R, Nuñez O, Monescillo A, Sánchez-Pobre P, Fernandez Castroagudin J, Vergara Gomez M, Fernández-Gil P, Lledo Navarro JL, Pons F, Romero M, Viladomiu L. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009 Aug 4;151(3):167-75.
 14. **Bosch J**, Garcia-Tsao G. Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is... Hepatology. 2009 Sep;50(3):674-7.
 15. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009 Mar;50(3):604-20.
 16. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82.
 17. Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Deninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D; European Network for Vascular Disorders of the Liver (EN-Vie). Collaborators (95): Bahr M, Elias E, Garcia-Pagan JC, Hadengue A, Janssen HL, Langlet P, Miranda H, Primignani M, Valla D, Adler M, Deltren P, Orlent H, Colle I, Leebeek FW, Tielemans WC, Rijken DC, van Buuren HR, Mensink PB, de Man RA, Malfliet JJ, Keizerwaard A, van Santen LA, Hansen B, ten Hove WR, van de Meeberg PC, van der Werf SD, Bac DJ, Adang RP, van Bergeijk JD, Beukers R, van de Vrie W, Berk L, van Tilburg AJ, Jansen PL, Poen AC, Drenth JP, Brouwer JT, Haagsma EB, Houben MH, Tjwa ET, van Esser JW, Fontenelle D, Robin D, Pauwels A, Lemerrier D, De Kerguenec C, Sondag L, Anslit T, Belghitti J, Cazals-Hatem D, Durand F, Vilgrain V, Buffet C, Gorla O, Dao MT, Mallat A, Bartoli E, Habersetszer F, Scoazec JY, Mathurin P, Nousbaum JB, Chagneau-Derrode C, Marteau P, Thabut D, De Ledinghen V, Bureau C, Carbonel N, Bacq Y, Hillaire S, Rosenbaum A, Rössle M, Marra F, Vizzutti F, Berzigotti A, Zoli M, Boschetti C, Dell'Era A, Nicolini A, Bellis L, Puoti C, Minoli G, Spinzi G, De Santis A, Merli M, Riggio O, Abraldes JG, Berzigotti A, Ayuso JR, Cervantes F, Fuster J, Garcia-Criado A, Gilabert R, Lozano R, Reverter JC, **Bosch J**. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010 Jan;51(1):210-8. IF: 11.355
 18. A Berzigotti, P Bellot, AD Gottardi, JC Garcia-Pagan, C Gagnon, J Spénard, **J Bosch**. NCX-1000, a Nitric Oxide-Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. Am J Gastroenterol. 2010 May;105(5):1094-101. Am J Gastroenterol advance online publication 17 November 2009; doi: 10.1038/ajg.2009.661
 19. Melgosa MT, Ricci GL, García-Pagan JC, Blanco I, Escribano P, Abraldes JG, Roca J, **Bosch J**, Barberà JA. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl. 2010 Jan 12;16(3):348-356.
-

20. Garcia-Tsao G, **Bosch J**. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010 Mar 4;362(9):823-32
 21. Mejias M, Garcia-Pras E, Gallego J, Mendez R, **Bosch J**, Fernández M. Relevance of the mTOR signalling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol. 2010 (52):529-539. IF: 7.056
 22. Berzigotti A, Abraldes JG, Tandon P, Erice E, Gilibert R, García-Pagan JC, **Bosch J**. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol. 2010 Jun;52(6):846-53.
 23. La Mura V, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, Carlos García-Pagán J, **Bosch J**. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology. 2010 Jun;51(6):2108-16.
 24. **Bosch J**. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010 Jun;51(6):2214-8.
 25. Coll M, Martell M, Raurell M, Ezkurdia N, Cuenca S, Hernández-Losa J, Esteban R, Guardia J, **Bosch J**, Genescà J. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Inter. 2010 Apr;30(4):593-602
 26. Garcia-Tsao G, **Bosch J**. Management of varices in cirrhosis. N Engl J Med 2010;362:2331-4
 27. Mehta G, Abraldes JG, Bosch J. Developments and controversies in the management of oesophageal and gastric varices. Gut, 2010 (6), 59: 701-705
 28. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, **Bosch J**. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370-9
 29. Solà E, Lens S, Guevara M, Martín-Llahí M, Fagundes C, Pereira G, Pavesi M, Fernández J, González-Abraldes J, Escorsell A, Mas A, Bosch J, Arroyo V, Ginès P. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010 Nov;52(5):1783-90.
 30. de Franchis R; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010 Oct;53(4):762-8.
 31. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010 Aug;53(2):273-82.
 32. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010 Sep;53(3):558-67.
 33. Tandon P, Saez R, Berzigotti A, Abraldes JG, Garcia-Pagan JC, Bosch J. A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol. 2010 Sep;105(9):1917-21.
 34. García-Pagán JC, Bosch J. ACP Journal Club. Early use of TIPS in patients with cirrhosis and variceal bleeding. Ann Intern Med. 2010 Nov 16;153(10):JC5-13
 35. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010 Dec;52(6):2044-52.
-

36. Thabut D, D'Amico G, Tan P, De Franchis R, Fabricius S, Lebrec D, Bosch J, Bendtsen F. Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population. *J Hepatol*. 2010 Dec;53(6):1029-34.
 37. Miraglia R, Luca A, Maruzzelli L, Spada M, Riva S, Caruso S, Maggiore G, Gridelli B, Bosch J. Measurement of hepatic vein pressure gradient in children with chronic liver diseases. *J Hepatol*. 2010 Oct;53(4):624-9.
 38. García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, García-Pagán JC. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. *J Hepatol*. 2010 Sep 25. [Epub ahead of print] PMID: 21159403
 39. Gracia-Sancho J, Russo L, García-Calderó H, García-Pagán JC, García-Cardena G, **Bosch J**. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. *Gut*. 2011 Apr;60(4):517-24
 40. Berzigotti A, Nicolau C, Bellot P, Abraldes JG, Gilibert R, García-Pagan JC, **Bosch J**. Evaluation of Regional Hepatic Perfusion (RHP) by Contrast-ENHANCED Ultrasound in Patients with Cirrhosis. *J Hepatol*. 2011 Aug;55(2):307-14.
 41. García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, **Bosch J**, García-Pagán JC. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. *J Hepatol*. 2011 Apr;54(4):660-5.
 42. Bureau C, Métivier S, D'Amico M, Péron JM, Otal P, Pagan JC, Chabbert V, Chagneau-Derrode C, Procopet B, Rousseau H, **Bosch J**, Vinel JP. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. *J Hepatol*. 2011 May;54(5):901-7.
 43. Llop E, de Juan C, Seijo S, García-Criado A, Abraldes JG, **Bosch J**, García-Pagán JC. Portal cholangiopathy: radiological classification and natural history. *Gut* 2011;60:853-860. doi:10.1136/gut.2010.230201.
 44. Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, Mura VL, García-Pagán JC, **Bosch J**. Insulin resistance and liver microcirculation in a rat model of early NAFLD. *J Hepatol*. 2011 Nov;55(5):1095-102. PMID: 21356259.
 45. Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, **Bosch J**. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. *Gut*. 2011;60:846-852. doi:10.1136/gut.2010.228023.
 46. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, **Bosch J**, García-Pagán JC. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. *Gut*. 2011 Aug;60(8):1133-8.
 47. Berzigotti A, Garcia-Tsao G, **Bosch J**, Grace N, Burroughs A, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ; the Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. *Hepatology*. 2011 Aug;54(2):555-561. doi: 10.1002/hep.24418.
 48. De Gottardi A, Seijo S, Milá M, Alvarez MI, Bruguera M, Abraldes JG, **Bosch J**, García-Pagán JC. Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. *J Cell Mol Med*. 2012 Sep;16(9):2017-2021. doi: 10.1111/j.1582-4934.2011.01496.x.
 49. Raffa S, Reverter JC, Seijo S, Tassies D, Abraldes JG, **Bosch J**, Garcia-Pagán JC. Hypercoagulability in Patients with Chronic Non-Cirrhotic Portal Vein Thrombosis. *Clin Gastroenterol Hepatol*. 2012;10:72-78. PMID: 21946303.
-

50. Lebrech D, **Bosch J**, Jalan R, Dudley FJ, Jessic R, Moreau R, Garcia-Pagan JC, Mookerjee RP, Chiossi E, Van Giersbergen PL, Kusic-Pajic A, Dingemans J. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. Eur J Clin Pharmacol. 2012 May;68(5):533-41 (Clinical Trial)
 51. **Bosch J**, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, de la Peña J, Escorsell A, García-Pagán JC, Genescà J, Hernández-Guerra M, Ripoll C, Planas R, Villanueva C. Portal hypertension: Recommendations for evaluation and treatment: Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd). Gastroenterol Hepatol. 2012 Volume 35, Issue 6, June–July 2012, Pages 421–450. GUIDELINE.
 52. Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, Bruix J, **Bosch J**, García-Pagan JC. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumours. J Hepatol. 2012 Jan;56(1):103-8.
 53. Russo L, Gracia-Sancho J, García-Calderó H, Marrone G, García-Pagán JC, García-Cardeña G, **Bosch J**. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology. 2012 Mar;55(3):921-30. doi: 10.1002/hep.24755.
 54. Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, Russo L, Rosado E, Roglans N, **Bosch J**, García-Pagán JC. PPAR α Activation Improves Endothelial Dysfunction And Reduces Fibrosis And Portal Pressure In Cirrhotic Rats. J Hepatol. 2012 May;56(5):1033-9.
 55. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, Abraldes JG, de la Peña J, Bañares R, Albillos A, **Bosch J**, García-Pagán JC. Efficacy and Safety of Anticoagulation on Patients with Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):776-83. PMID:22289875.
 56. Chandok N, Kamath PS, Blei A, **Bosch J**, Carey W, Grace N, Kowdley KV, Benner K, Groszmann RJ. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther. 2012; 35: 904-912. doi: 10.1111/j.1365-2036.2012.05050.x. PMID: 22380529.
 57. de Souza AR, La Mura V, Reverter E, Seijo S, Berzigotti A, Askenazhi E, García-Pagán JC, Abraldes JG, **Bosch J**. Patients Whose First Episode of Bleeding Occurs While Taking a β -Blocker Have High Long-Term Risks of Rebleeding and Death. Clin Gastroenterol Hepatol. 2012 Jun;10(6):670-6. PMID: 22366180.
 58. D'Amico M, Mejías M, García-Pras E, G Abraldes J, Garcia-Pagan JC, Fernández M, **Bosch J**. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2012 May;302(10):G1191-8. Epub 2012 Mar 8.
 59. Shneider BL, **Bosch J**, de Franchis R, Emre SH, Groszmann RJ, Ling SC, Lorenz JM, Squires RH, Superina RA, Thompson AE, Mazariegos GV. Portal Hypertension in Children: Expert Pediatric Opinion on the Report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant. 2012 Aug;16(5):426-437. doi: 10.1111/j.1399-3046.2012.01652.x.
 60. Erice E, Llop E, Berzigotti A, G Abraldes J, Conget I, Seijo S, Reverter E, Albillos A, **Bosch J**, Garcia-Pagan JC. Insulin Resistance in Patients with Cirrhosis and Portal Hypertension. Am J Physiol Gastrointest Liver Physiol. 2012 Jun;302(12):G1458-65. PMID:22492691
 61. Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Monclús M, **Bosch J**, García-Pagán JC. Interaction Between No And Cox Pathways Modulating Hepatic Endothelial Cells From Control And Cirrhotic Rats. J Cell Mol Med. 2012 Oct;16(10):2461-70. doi: 10.1111/j.1582-4934.2012.01563.x. PMID:22436078
 62. Pasarín M, La Mura V, Gracia-Sancho J, García-Calderó H, Rodríguez-Vilarrupla A, García-Pagán JC, **Bosch J**, Abraldes JG. Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. PLoS One. 2012;7(4):e32785. doi: 10.1371/journal.pone.0032785.
-

63. Seijo S, Reverter E, Miquel R, Berzigotti A, Abraldes JG, **Bosch J**, García-Pagán JC. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. *Dig Liver Dis.* 2012 Oct;44(10):855-60. PMID:22721839
64. De Gottardi A, Berzigotti A, Seijo S, D'Amico M, Thormann W, Abraldes JG, García-Pagán JC, **Bosch J**. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. *Am J Clin Nutr.* 2012 Sep;96(3):584-90 PMID:22811444. CLINICAL TRIAL.
65. Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, Luca A, Zipprich A, Abraldes JG, Nevens F, Vinel JP, Sauerbruch T, **Bosch J**. Use of Early-TIPS for High-Risk Variceal Bleeding. Results of a post-RCT Surveillance Study. *J Hepatol.* 2013 Jan;58(1):45-50. doi: 10.1016/j.jhep.2012.08.020.
66. Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, **Bosch J**, Garcia-Pagán JC. Recombinant Human Manganese Superoxide Dismutase Reduces Liver Fibrosis and Portal Pressure in CCL(4)-Cirrhotic Rats. *J Hepatol.* 2013 Feb;58(2):240-6. doi: 10.1016/j.jhep.2012.09.010.
67. Marrone G, Russo L, Rosado E, Hide D, García-Cardena G, García-Pagán JC, **Bosch J**, Gracia-Sancho J. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. *J Hepatol.* 2013 Jan;58(1):98-103. doi: 10.1016/j.jhep.2012.08.026. PMID: 22989565
68. Crespo G, Carrión JA, Coto-Llerena M, Mariño Z, Lens S, Pérez-Del-Pulgar S, García-Retortillo M, Miquel R, **Bosch J**, Navasa M, Forns X. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. *J Gastroenterol.* 2013 Jun;48(6):762-9. doi: 10.1007/s00535-012-0680-2. PMID: 23011083
69. A Berzigotti, E Erice, R Gilabert, E Reverter, JG. Abraldes, JC García-Pagan, **J Bosch**. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. *Am J Gastroenterol.* 2013 Jan;108(1):75-82. doi: 10.1038/ajg.2012.362
70. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, Pinzani M, **Bosch J**. Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients with Compensated Cirrhosis. *Gastroenterology.* 2013 Jan;144(1):102-111.e1. doi: 10.1053/j.gastro.2012.10.001. PMID:23058320
71. La Mura V, Pasarín M, Meireles CZ, Miquel R, Rodriguez-Vilarrupla A, Hide D, Gracia-Sancho J, García-Pagán JC, **Bosch J**, Abraldes JG. Effects of simvastatin administration on rats with LPS induced liver microvascular dysfunction. *Hepatology.* 2013 Mar;57(3):1172-81. doi: 10.1002/hep.26127.
72. Pascoli MD, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, **Bosch J**, García-Pagán JC. Resveratrol Improves Intrahepatic Endothelial Dysfunction and Reduces Hepatic Fibrosis and Portal Pressure in Cirrhotic Rats. *J Hepatol.* 2013 May;58(5):904-10. doi: 10.1016/j.jhep.2012.12.012. PMID: 23262250
73. Gracia-Sancho J, García-Calderó H, Hide D, Marrone G, Guixé-Muntet S, Peralta C, García-Pagán JC, Abraldes JG, **Bosch J**. Simvastatin Maintains Function and Viability of Steatotic Rat Livers Procured for Transplantation. *J Hepatol.* 2013 Jun;58(6):1140-6. doi: 10.1016/j.jhep.2013.02.005. PMID:23428876
74. Seijo S, Lozano JJ, Alonso C, Reverter E, Miquel R, Abraldes JG, Martínez-Chantar ML, Garcia-Criado A, Berzigotti A, Castro A, Mato JM, **Bosch J**, Garcia-Pagan JC. Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. *Am J Gastroenterol.* 2013 Jun;108(6):926-32. doi: 10.1038/ajg.2013.11 PMID:23419380
75. Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, G Abraldes J, García-Valdecasas JC, Navasa M, García-Pagán JC, **Bosch J**. Hemodynamic response to propranolol in patients with recurrent HCV-related cirrhosis after

- liver transplantation: A case-control study. Liver Transpl. 2013 Apr;19(4):450-6. doi: 10.1002/lt.23614. PMID:23408436.
76. Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García-Pagan JC, **Bosch J**. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One. 2013;8(3):e58742. doi: 10.1371/journal.pone.0058742. Epub 2013 Mar 8. PMID:23520531.
 77. Berzigotti A, Reverter E, García-Criado A, Abraldes JG, Cerini F, García-Pagán JC, **Bosch J**. Reliability of the estimation of total hepatic blood flow by doppler ultrasound in patients with cirrhotic portal hypertension. J Hepatol. 2013 Oct;59(4):717-22. doi: 10.1016/j.jhep.2013.04.037.
 78. Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Tripathi D, García-Calderó H, Bosch J, García-Pagán JC. Terutroban, A TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology. 2013 Oct;58(4):1424-1435. doi: 10.1002/hep.26520
 79. Delgado MG, Gracia-Sancho J, Marrone G, Rodríguez-Vilarrupla A, Deulofeu R, G Abraldes J, **Bosch J**, Garcia-Pagan JC. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2013 Oct;305(7):G496-G502. PMID:23886859.
 80. Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, Cirera I, Aracil C, Sala M, Hernandez-Guerra M, Llop E, Escorsell A, Catalina MV, Cañete N, Albillos A, Villanueva C, Abraldes JG, Bañares R, **Bosch J**. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology. 2013 Dec; 58 (6):2079-88. doi: 10.1002/hep.26629. PMID:23908019. Clinical trial.
 81. Berzigotti A, Abraldes JG, Bosch J. Letter to the Editor regarding "Liver stiffness is influenced by a standardized meal in patients with chronic HCV hepatitis at different stages of fibrotic evolution". Hepatology. 2013 May 23. doi: 10.1002/hep.26501. [Epub ahead of print] PMID:23703869
 82. Reverter E, Blasi A, Abraldes JG, Martínez-Palli G, Seijo S, Turon F, Berzigotti A, Balust J, Bosch J, García-Pagán JC. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2013 May 22. doi: 10.1111/liv.12229. [Epub ahead of print] PMID:23763484.
 83. Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, Turon F, Hernandez-Gea V, Bosch J, Garcia-Pagan JC. Idiopathic portal hypertension: Natural history and long-term outcome. Hepatology. 2014 Jun;59 (6):2276-852013 doi: 10.1002/hep.26904. PMID:24155091
 84. Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, Keough A, Llop E, González A, Seijo S, Berzigotti A, Ma M, Genescà J, Bosch J, García-Pagán JC, Abraldes JG. A MELD-Based Model to Determine Risk of Mortality Among Patients with Acute Variceal Bleeding. Gastroenterology. 2014 Feb; 146 (2):412-19. Doi 10.1053/j.gastro.2013.10.018. PMID:24148622
 85. Berzigotti A, Reig M, Abraldes JG, Bruix J, **Bosch J**, García-Pagán JC. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Ann Surg. 2013 Nov 20. [Epub ahead of print] No abstract available. PMID:24263313
 86. Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, **Bosch J**, Mendez R, Fernandez M. Disruption of negative feedback loop between vasohibin-1 and VEGF decreases portal pressure, angiogenesis and fibrosis in cirrhotic rats. Hepatology. 2014 Aug 60 (2): 633-47. doi: 10.1002/hep.26995. PMID: 24390792
 87. Gracia-Sancho J, **Bosch J**. Is it tea time for portal hypertension? Clin Sci (Lond). 2014 May 1;126(9):631-2. doi: 10.1042/CS20130810. PMID:24354920
-

88. Hernández-Guerra M, González-Méndez Y, de Ganzo ZA, Salido E, García-Pagán JC, Abrante B, Malagón AM, **Bosch J**, Quintero E. Role of gap junctions modulating hepatic vascular tone in liver cirrhosis. *Liver Int.* 2013 Dec 18. doi: 10.1111/liv.12446. [Epub ahead of print]. PMID:24350605
 89. Crespo G, Lens S, Gambato M, Carrión JA, Mariño Z, Londoño MC, Miquel R, **Bosch J**, Navasa M, Forns X. Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C. *Am J Transplant.* 2014 Feb;14(2):375-83. doi: 10.1111/ajt.12594. PMID:24410892.
 90. Berzigotti A, **Bosch J**, Boyer TD. Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. *Hepatology.* 2014 Feb;59(2):729-31. doi: 10.1002/hep.26652. Epub 2013 Dec 24. Clinical Perspective.
 91. Tsochatzis EA, **Bosch J**, Burroughs AK. Liver cirrhosis. *Lancet.* 2014 May 17: 383 (9930) : 1749-61. doi: 10.1016/S0140-6736(14)60121-5. PMID:24480518
 92. Berzigotti A, **Bosch J**. Pharmacologic Management of Portal Hypertension. *Clinics in Liver Disease.* 2014 May;18(2):303-317. doi:10.106/j.cld.2013.12.003. Epub 2014 Feb 25. Review. PMID: 24679496.
 93. Casu S, Berzigotti A, Abraldes JG, Baringo MA, Rocabert L, Hernández-Gea V, García-Pagán JC, Bosch J. A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. *Liver Int.* 2014 Mar 14. doi:10.1111/liv.12522. [Epub ahead of print] PubMed PMID: 24628960.
 94. Gracia-Sancho J, Guixé-Muntet S, Hide D, Bosch J. Modulation of autophagy for the treatment of liver diseases. *Expert Opin Investig Drugs.* 2014 Jul; 23 (7):965-77. PubMed PMID: 24749698.
 95. Hide D, Ortega-Ribera M, Fernandez-Iglesias A, Fondevila C, Salvado MJ, Arola L, Garcia-Pagan JC, Mancini A, Bosch J, Gracia-Sancho J. A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischemia and reperfusion injury. *Clin Sci (Lond).* 2014 Oct 1: 127(8):527-37. PubMed PMID: 24754522.
 96. Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M. Antiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. *Gut.* 2015 Apr;64(4):657-66. doi: 10.1136/gutjnl-2014-307138. Epub 2014 May 21.
 97. La Mura V, Pasarín M, Rodríguez-Vilarrupla a, García-Pagan JC, Bosch J, Abraldés JG. Liver Sinusoidal Endothelial Dysfunction After LPS Administration: a Role for Inducible-Nitric Oxide Synthase. *J Hepatol.* 2014 Jul 16. pii:S0168-8278(14)00483-8. doi:10.1016/j.jhep.2014.07.014. [Epub ahead of print] PubMed PMID: 25038487.
 98. Mariño Z, Mensa L, Crespo G, Miquel R, Bruguera M, Pérez-Del-Pulgar S, Bosch J, Forns X, Navasa M. Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. *J Hepatol.* 2014. Aug; 61 (2): 270-7. Doi: 10.1016/j.jhep.2014.03.029. PubMed PMID:24703854.
 99. Procopet B, Berzigotti A, Abraldes JG, Turon F, Hernandez-Gea V, García-Pagán JC, **Bosch J**. Real-time shearwave elastography: Applicability, reliability and accuracy for clinically significant **portal** hypertension. *J Hepatol.* 2014 Dec 13. pii: S0168-8278(14)00925-8.
 100. Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García-Pagán JC, **Bosch J**, Gracia-Sancho J. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. *Gut.* 2015 Sep;64(9):1434-43. doi: 10.1136/gutjnl-2014-308338. Epub 2014 Dec 10.
 101. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. *Hepatology.* 2015 Feb;61(2):526-36. doi: 10.1002/hep.27431. Epub 2015 Jan 5.
 102. Fili D, Falletta C, Luca A, Hernandez Baravoglia C, Clemenza F, Miraglia R, Scardulla C, Tuzzolino F, Vizzini G, Gridelli B, Bosch J. Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. *Dig Liver Dis.* 2015 Sep 3. pii: S1590-8658(15)00609-X. doi: 10.1016/j.dld.2015.08.014. [Epub ahead of print]
-

103. Villanueva C, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, Bosch J. Development of hyperdynamic circulation and response to β -blockers in compensated cirrhosis with portal hypertension. *Hepatology*. 2015 Sep 30. doi: 10.1002/hep.28264. [Epub ahead of print]
 104. Seijo S, Lozano JJ, Alonso C, Miquel R, Berzigotti A, Reverter E, Turon F, Martínez-Chantar ML, Castro A, Mato JM, Hernández-Gea V, Bosch J, García-Pagán JC. Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. *Liver Int*. 2015 Sep 23. doi: 10.1111/liv.12972. [Epub ahead of print]
 105. Shneider BL, de Ville de Goyet J, Leung D, Srivastava A, Ling SC, Duché M, McKiernan P, Superina R, Squires RH, Bosch J, Groszmann R, Sarin S, de Franchis R, Mazariegos G. Primary Prophylaxis of Variceal Bleeding in Children and the Role of MesoRex Bypass-Summary of the Baveno VI Pediatric Satellite Symposium. *Hepatology*. 2015 Sep 11. doi: 10.1002/hep.28153. [Epub ahead of print]
 106. de Souza AR, La Mura V, Berzigotti A, García-Pagán JC, Abraldes JG, Bosch J. Prognosis of acute variceal bleeding: is being on beta-blockers an aggravating factor? A short-term survival analysis. *Hepatology*. 2015 Sep 4. doi: 10.1002/hep.28151. [Epub ahead of print] PMID:26340692
 107. Bosch J. EASL Recognition Award Recipient 2015: Prof. Roberto de Franchis. *J Hepatol*. 2015 Oct;63(4):787-8. doi: 10.1016/j.jhep.2015.07.019. Epub 2015 Aug 10. No abstract available.
 108. Silva-Junior G, Baiges A, Turon F, Torres F, Hernández-Gea V, Bosch J, García-Pagán JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. *Hepatology*. 2015 Aug 3. doi: 10.1002/hep.28031. [Epub ahead of print]
 109. Gracia-Sancho J, Maeso-Díaz R, Bosch J. Pathophysiology and a Rational Basis of Therapy. *Dig Dis*. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6.
 110. Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, Gracia-Sancho J, García-Pagán JC. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. *Am J Physiol Gastrointest Liver Physiol*. 2015 Sep 1;309(5):G301-9. doi: 10.1152/ajpgi.00010.2015. Epub 2015 Jul 2.
 111. Reverter E, Mesonero F, Seijo S, Martínez J, Abraldes JG, Peñas B, Berzigotti A, Deulofeu R, Bosch J, Albillos A, García-Pagán JC. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. *Am J Gastroenterol*. 2015 Jul;110(7):985-92. doi: 10.1038/ajg.2015.185. Epub 2015 Jun 16.
 112. Amat-Roldan I, Berzigotti A, Gilabert R, Bosch J. Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. *Radiology*. 2015 Oct;277(1):268-76. doi: 10.1148/radiol.2015141941. Epub 2015 May 28.
 113. Bosch J, Forns X. Therapy. Statins and liver disease: from concern to 'wonder' drugs? *Nat Rev Gastroenterol Hepatol*. 2015 Jun;12(6):320-1. doi: 10.1038/nrgastro.2015.78. Epub 2015 May 12.
 114. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. *J Hepatol*. 2015 Apr;62(1 Suppl):S121-30. doi: 10.1016/j.jhep.2015.01.003. Review.
 115. Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. *Clin Gastroenterol Hepatol*. 2015 Oct;13(10):1846-1853.e1. doi: 10.1016/j.cgh.2015.04.013. Epub 2015 Apr 23.
 116. Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. *Hepatol Int*. 2015 Apr;9(2):183-91. doi: 10.1007/s12072-015-9613-5. Epub 2015 Mar 5.
-

117. Cerini F, Gonzalez JM, Torres F, Puente Á, Casas M, Vinaixa C, Berenguer M, Ardevol A, Augustin S, Llop E, Senosiain M, Villanueva C, de la Peña J, Bañares R, Genescà J, Sopeña J, Albillos A, Bosch J, Hernández-Gea V, Garcia-Pagán JC. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. *Hepatology*. 2015 Aug;62(2):575-83. doi: 10.1002/hep.27783. Epub 2015 Apr 27.
118. Villanueva C, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, **Bosch J**. Development of hyperdynamic circulation and response to β -blockers in compensated cirrhosis with portal hypertension. *Hepatology*. 2015 Sep 30. doi: 10.1002/hep.28264. [Epub ahead of print]
119. Garcia-Tsao G, Bosch J. Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. *Clin Gastroenterol Hepatol*. 2015 Jul 17. pii: S1542-3565(15)00970-2. doi: 10.1016/j.cgh.2015.07.012. [Epub ahead of print] Review.

(full list of publication in Pubmed: [Bosch J AND portal] [Bosch J AND liver])
